Pharvaris NV (PHVS)
22.29
+1.25
(+5.94%)
USD |
NASDAQ |
Nov 22, 16:00
22.08
-0.20
(-0.92%)
After-Hours: 20:00
Pharvaris Shareholders Equity (Quarterly): 331.48M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 331.48M |
June 30, 2024 | 356.69M |
March 31, 2024 | 387.87M |
December 31, 2023 | 424.53M |
September 30, 2023 | 162.09M |
June 30, 2023 | 188.80M |
March 31, 2023 | 140.83M |
December 31, 2022 | 160.07M |
September 30, 2022 | 182.00M |
Date | Value |
---|---|
June 30, 2022 | 199.07M |
March 31, 2022 | 213.06M |
December 31, 2021 | 232.05M |
September 30, 2021 | 249.87M |
June 30, 2021 | 264.46M |
March 31, 2021 | 276.16M |
December 31, 2020 | 117.81M |
September 30, 2020 | 45.42M |
December 31, 2019 | 20.92M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
20.92M
Minimum
Dec 2019
424.53M
Maximum
Dec 2023
219.62M
Average
206.06M
Median
Shareholders Equity (Quarterly) Benchmarks
uniQure NV | 55.82M |
ProQR Therapeutics NV | 27.90M |
Merus NV | 703.26M |
argenx SE | -- |
Pharming Group | 225.79M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 349.79M |
Total Liabilities (Quarterly) | 18.30M |